This week’s topics include an intensive lifestyle intervention and its association with type-2 diabetes remission, strategies for multivessel revascularization in patients with diabetes, and more.

CardioExchange invited contributors and members to offer predictions for 2013. Several of these folks also offered predictions for last year and helped assess the most important developments in cardiology in 2012. What are your predictions for the year?   Steven E Nissen, MD The IMPROVE-IT Trial will complete and show no reduction in morbidity-mortality with addition of ezetimibe to simvastatin The new NCEP Cholesterol Guidelines will be released and will no longer recommend treating to target LDL levels. The HPS Thrive Study will complete and show no benefits for the combination of niacin and laropiprant…. Continue Reading

CardioExchange invited several members and participants to give us a list of what they consider the top three most important developments in cardiology in 2012.  The same CardioExchange members offer predictions for 2013, which you can view here. Also, for comparison, check out last year’s predictions for 2012 to see which came to fruition. What would your choices have been? Any sins of inclusion or exclusion here in your opinion? Join the conversations.   Steven E Nissen, MD The FREEDOM trial clearly demonstrating that CABG is superior to PCI in diabetic patients The failure… Continue Reading

This week’s topics include a study on ICD programming to reduce inappropriate therapy and mortality, a clinical review of diagnosing and managing supraventricular tachycardia, the Global Burden of Disease Study 2010, and more.

A visual journal of open and minimally invasive cardiac surgeries — side by side

John Ryan reviews the latest data and suggests that DVT/PE be managed as a chronic condition. Are you using apixaban in these patients, and how long are you treating them for?

This week’s topics include a comparison of warfarin and new oral anticoagulants for managing AF and VTE, two studies of a monoclonal antibody to PCSK9 in patients with hypercholesterolemia, and more.

Thoughts from Dr. Wes about the strengths and limitations of AliveCor’s ECG Case for iPhone, newly approved by the FDA

This week’s topics include the association between aldosterone-antagonist therapy and mortality and readmission among patients with HF and reduced EF, warfarin therapy after bioprosthetic AVR, and more.